About MPS Pharmaa Limited
MPS Pharmaa Limited is a publicly listed company based in Palwal (India). It operates as a manufacturing and exporting of pharmaceutical medicines in India. Its Indian entity Mps Pharmaa Limited reported revenue of ₹4.8 Lakh. MPS Pharmaa Limited offers products and services including Anti-allergic Capsules and Anti-inflammatory Tablets. Its focus areas include Manufacturing, Formulations and Exports, International Distribution and Pharmaceuticals.
Company details
MPS Pharmaa Limited was established in 1997 as a WHO and GMP certified entity, with manufacturing processes designed to meet USFDA standards. A variety of pharmaceutical products, including anti-allergic and anti-inflammatory medicines, antihypertensives, analgesics, and antibiotics, are produced and exported to numerous countries. The company is managed by qualified professionals, and leadership in quality and customer service has been achieved through state-of-the-art processes and competitive pricing. Changes to the company name from Advik Laboratories Limited were effected by the Registrar of Companies in 2022.
- Headquarters Palwal, India
- Stage Public
- SectorsHealthcare
- Email••••••••
- Legal Name Mps Pharmaa Limited
- Annual Revenue₹4.8 Lakh
FY 2025 · -49% YoY
- Net Loss-₹89.8 Lakh
FY 2025 · -1882% margin
- EBITDA-₹71.7 Lakh
FY 2025 · -1502% margin
Associated legal entities of MPS Pharmaa Limited
MPS Pharmaa Limited operates through Mps Pharmaa Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Mps Pharmaa Limited Listed CIN L74899HR1994PLC038300 | Active | 09 Sep 1994 | Gurgaon, Haryana | ₹0.0 Cr | 13 | 6 | View details |
Products & Services of MPS Pharmaa Limited
MPS Pharmaa Limited offers a comprehensive portfolio of products and services, including Anti-allergic Capsules and Anti-inflammatory Tablets.
Anti-allergic capsules are manufactured and exported for various medical uses
Anti-inflammatory tablets are produced and distributed for treating inflammation and related conditions
Board of directors of Mps Pharmaa Limited (MPS Pharmaa Limited)
Mps Pharmaa Limited is the primary company behind MPS Pharmaa Limited. The board of Mps Pharmaa Limited currently have 4 directors; the longest-serving is Peeyush Kumar Aggarwal, appointed in 2013. 23 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Peeyush Kumar Aggarwal DIN 00090423 | Managing Director | 31 Jul 2013 | 13 yrs 2 mo | Mps Pharmaa Limited |
| Madhu Sharma DIN 06947852 | Director | 31 Jan 2017 | 9 yrs 8 mo | Mps Pharmaa Limited |
| Ram Niwas Sharma DIN 08427985 | Director | 23 Aug 2019 | 7 yrs 1 mo | Mps Pharmaa Limited |
| Ajay Sharma DIN 03344008 | Director | 13 Jul 2023 | 3 yrs 3 mo | Mps Pharmaa Limited |
IPO & Listings of MPS Pharmaa Limited
MPS Pharmaa Limited is a publicly listed company on the BSE with ticker symbol ADVIKLA in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- Listed onBSE: ADVIKLA
- Listed entityMPS PHARMAA LIMITED
- Exchange sectorHealth technology
- ISININE537C01019
- Share price₹2.08 · 2026-10-12
- Market capitalisation₹4.0 Cr
- EPS (diluted, trailing year)₹-0.54
- Volume (last session)600
Financials of MPS Pharmaa Limited
Figures of Mps Pharmaa Limited, the primary company behind MPS Pharmaa Limited, for FY 2025. Revenue was ₹4.8 Lakh (-49% year on year). Net loss was -₹89.8 Lakh (-1882% margin). EBITDA was -₹71.7 Lakh (-1502% margin). Revenue has grown at a compounded annual rate of -45% over three years and +26% over five years.
- ₹4.8 LakhRevenue · FY 2025 · -49% YoY
- -₹89.8 LakhNet loss · -1882% margin
- -₹71.7 LakhEBITDA · -1502% margin
- ₹19.11 CrPaid-up capital
- 13Employees (provident fund records)
- -45%Revenue CAGR, 3 years
- +26%Revenue CAGR, 5 years
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | – | -₹1.0 Cr | -₹0.9 Cr |
| 2024 | – | -₹0.9 Cr | -₹0.8 Cr |
| 2023 | – | -₹0.8 Cr | -₹0.8 Cr |
| 2022 | – | -₹1.1 Cr | -₹0.9 Cr |
| 2021 | ₹0.0 Cr | -₹0.1 Cr | -₹0.7 Cr |
Balance sheet, profit and loss, cash flow and ratios of Mps Pharmaa Limited are on its company page.
Detailed financial statements for MPS Pharmaa Limited
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Top companies in Pharmaceuticals & Distribution
10 companies that operate in the same segment as MPS Pharmaa Limited (Pharmaceuticals & Distribution), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | Kenilworth, Warwickshire, United Kingdom | – | USD 64.93 B | 781 | |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | – | USD 33.23 B | 28,000 | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | – | USD 61.16 B | 55,000 | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | – | USD 65.18 B | 47,000 | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | Foster City, California, United States | – | USD 29.45 B | 17,600 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 213.52 M | USD 29.62 M | 225 | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | Libertyville, Illinois, United States | – | USD 44.33 B | 3,710 | |
Medicines and health products are retailed through pharmacy outlets. | 2006 | Hyderabad, Telangana, India | USD 268.78 M | USD 734.57 M | 25,010 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Mps Pharmaa Limited
Complete news archive for MPS Pharmaa Limited
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about MPS Pharmaa Limited
MPS Pharmaa Limited is headquartered in Palwal, India. It is registered at Palwal, Haryana, India.
The primary company behind MPS Pharmaa Limited, Mps Pharmaa Limited, reported revenue of ₹4.8 Lakh for FY 2025, down 49% year on year.
MPS Pharmaa Limited was established in 1997 as a WHO and GMP certified entity, with manufacturing processes designed to meet USFDA standards. A variety of pharmaceutical products, including anti-allergic and anti-inflammatory medicines, antihypertensives, analgesics, and antibiotics, are produced and exported to numerous countries. The company is managed by qualified professionals, and leadership in quality and customer service has been achieved through state-of-the-art processes and competitive pricing. Changes to the company name from Advik Laboratories Limited were effected by the Registrar of Companies in 2022.
MPS Pharmaa Limited offers Anti-allergic Capsules and Anti-inflammatory Tablets.
Yes, MPS Pharmaa Limited is publicly traded on BSE under the ticker symbol ADVIKLA.
MPS Pharmaa Limited operates through Mps Pharmaa Limited.
The legal entities of MPS Pharmaa Limited currently have 6 directors, including Ram Niwas Sharma, Peeyush Kumar Aggarwal, Pooja Chuni and others.